Short Interest in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Rises By 936.6%

Posted by Patrick Bannon on Dec 25th, 2025

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD – Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 79,925 shares, an increase of 936.6% from the November 30th total of 7,710 shares. Based on an average trading volume of 237,817 shares, the short-interest ratio is presently 0.3 days. Currently, 0.7% of the company’s stock are short sold. Currently, 0.7% of the company’s stock are short sold. Based on an average trading volume of 237,817 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on HKPD

Hong Kong Pharma Digital Technology Stock Performance

Shares of HKPD traded down $0.01 during mid-day trading on Thursday, hitting $0.75. 26,297 shares of the company’s stock were exchanged, compared to its average volume of 157,544. Hong Kong Pharma Digital Technology has a twelve month low of $0.68 and a twelve month high of $3.79. The firm has a fifty day moving average of $1.04 and a two-hundred day moving average of $1.23.

Hong Kong Pharma Digital Technology Company Profile

(Get Free Report)

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.